Beta-blockers in heart failure with preserved ejection fraction: a meta-analysis (Q38230776)

31 August 2017

0 references

Beta-blockers in heart failure with preserved ejection fraction: a meta-analysis (English)

1 reference

Heart failure with preserved ejection fraction

31 August 2017

0 references

1 reference

1 reference

1 reference

5

Franz H Messerli

1 reference

31 August 2017

Chirag Bavishi

1

1 reference

31 August 2017

Saurav Chatterjee

series ordinal

2

1 reference

31 August 2017

Sameer Ather

series ordinal

3

1 reference

31 August 2017

Dipen Patel

series ordinal

4

1 reference

31 August 2017

language of work or name

1 reference

1 March 2015

1 reference

31 August 2017

Heart Failure Reviews

1 reference

31 August 2017

20

1 reference

31 August 2017

2

1 reference

31 August 2017

193-201

1 reference

https://scigraph.springernature.com/pub.10.1007/s10741-014-9453-8

31 August 2017

0 references

cites work

2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines

1 reference

https://api.crossref.org/works/10.1007%2FS10741-014-9453-8

Trends in prevalence and outcome of heart failure with preserved ejection fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-014-9453-8

Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-014-9453-8

Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-014-9453-8

Treatment of patients with heart failure and preserved ejection fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-014-9453-8

Benefits of β blockers in patients with heart failure and reduced ejection fraction: network meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-014-9453-8

Effects of beta-blockers on heart failure with preserved ejection fraction: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-014-9453-8

Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-014-9453-8

Mortality and morbidity of newly diagnosed heart failure with preserved systolic function treated with β-blockers: a propensity-adjusted case-control populational study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-014-9453-8

Relation of beta-blocker use with frequency of hospitalization for heart failure in patients with left ventricular diastolic dysfunction (from the Heart and Soul Study)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-014-9453-8

Beta-blockers in older patients with heart failure and preserved ejection fraction: class, dosage, and outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-014-9453-8

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-014-9453-8

Current methods of the US Preventive Services Task Force: a review of the process

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-014-9453-8

Beta-blockers and outcome in heart failure and atrial fibrillation: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-014-9453-8

Hazard ratio in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-014-9453-8

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-014-9453-8

Quantifying heterogeneity in a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-014-9453-8

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-014-9453-8

Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Fail

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-014-9453-8

Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-014-9453-8

Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-014-9453-8

Prescription of beta-blockers in patients with advanced heart failure and preserved left ventricular ejection fraction. Clinical implications and survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-014-9453-8

Effect of statins, angiotensin-converting enzyme inhibitors, and beta blockers on survival in patients >or=65 years of age with heart failure and preserved left ventricular systolic function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-014-9453-8

Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-014-9453-8

Value of medical therapy in patients >80 years of age with heart failure and preserved ejection fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-014-9453-8

Comparison of β-blocker effectiveness in heart failure patients with preserved ejection fraction versus those with reduced ejection fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-014-9453-8

Effect of beta blocker therapy on survival of patients with heart failure and preserved systolic function following hospitalization with acute decompensated heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-014-9453-8

The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-014-9453-8

Therapy for diastolic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-014-9453-8

Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-014-9453-8

Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-014-9453-8

Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDIC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-014-9453-8

2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-014-9453-8

Relation of beta-blocker-induced heart rate lowering and cardioprotection in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-014-9453-8

A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-014-9453-8

Heart failure and chronic obstructive pulmonary disease the quandary of Beta-blockers and Beta-agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-014-9453-8

Rationale and design of the beta-blocker in heart failure with normal left ventricular ejection fraction (beta-PRESERVE) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-014-9453-8

Angiotensin-converting enzyme inhibitors prescription is associated with longer survival among patients hospitalized for congestive heart failure who have preserved systolic function: a long-term follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-014-9453-8

Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction

21 January 2018

1 reference

12 December 2020

Association of beta-blocker use with mortality among patients with congestive heart failure in the Cardiovascular Health Study (CHS)

1 reference

12 December 2020

Beta-blockers for hypertension

1 reference

12 December 2020

Discharge use of carvedilol is associated with higher survival in Japanese elderly patients with heart failure regardless of left ventricular ejection fraction

1 reference

12 December 2020

Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction > or = 40% treated with diuretics

1 reference

12 December 2020

10.1007/S10741-014-9453-8

Identifiers

DOI

1 reference

31 August 2017

1 reference